{"id":"aav8-hcoch","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT04884594"],"aliases":[],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"AAV8-hCocH","companyId":"w-michael-hooten","mechanism":{"target":"","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123006,"model":"claude-sonnet-4-5-20250929"},"companyName":"W. Michael Hooten","competitors":[],"description":"AAV8-hCocH is an investigational gene therapy in Phase 1 development. The therapy utilizes an adeno-associated virus serotype 8 (AAV8) vector, though its specific molecular target and therapeutic indication have not been publicly disclosed. Limited information is available about this early-stage experimental treatment.","genericName":"AAV8-hCocH","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":1,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}